International Journal of Clinical Medicine

Volume 3, Issue 4 (July 2012)

ISSN Print: 2158-284X   ISSN Online: 2158-2882

Google-based Impact Factor: 0.52  Citations  h5-index & Ranking

Pathological Complete Remission in Young Colon Cancer Patient with a Large Liver Metastasis after FOLFOX-4/Bevacizumab Treatment – A Case Report

HTML  XML Download Download as PDF (Size: 657KB)  PP. 307-310  
DOI: 10.4236/ijcm.2012.34061    3,754 Downloads   6,737 Views  Citations

ABSTRACT

Introduction. Pathological complete remission of liver metastases is a rare colon cancer treatment outcome with increased 5-year survival of 76%. Case report. Metastatic colorectal cancer patient with pathological complete remission of large hepatic metastasis after palliative chemotherapy in combination with bevacizumab is presented. Solitary liver metastasis measuring 8 cm was observed in computed tomography (CT) scan before combined treatment. The best radiological response during treatment with FOLFOX-4 and bevacizumab therapy was partial remission and patient underwent partial hepatectomy. Since the operation material was free of viable adenocarcinoma cells the effect of FOLFOX-4 in combination with bevacizumab treatment was interpreted as the pathological complete remission. Conclusion. Use of combination chemotherapy and targeted therapy with the aim to reduce initially unresectable liver metastasis is the best option to achieve complete pathological remission and significantly prolong survival.

Share and Cite:

E. Skuja, A. Āboliņš, I. Priedīte, G. Purkalne, I. Štrumfa, J. Vilmanis, D. Kalniete, E. Miklaševičs and J. Gardovskis, "Pathological Complete Remission in Young Colon Cancer Patient with a Large Liver Metastasis after FOLFOX-4/Bevacizumab Treatment – A Case Report," International Journal of Clinical Medicine, Vol. 3 No. 4, 2012, pp. 307-310. doi: 10.4236/ijcm.2012.34061.

Copyright © 2024 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.